A new HPAPI manufacturing unit has been opened in France, with the capability to make a contraceptive with a superior safety profile and high level of biodegradability.
List view / Grid view
Active Pharmaceutical Ingredient (API)
Filter the results
The expansion will be specifically designed to manufacture high-potency active pharmaceutical ingredients (HPAPIs) and complex antibody-drug conjugates (ADCs).
Product recalls due to contamination issues can be extremely costly for companies, in addition to the associated health implications. In this article, Marc Baiget Francesch explores the potential risks associated with N-nitrosodimethylamine (NDMA) contamination, why is it such a frequent contaminant and how to detect and eliminate the risks.
A report suggests that India’s CMO market has recently attracted investment from global private equity firms due to favourable government policies.
Four APIs are being considered by the FDA for its bulk drug substances list for potential use by outsourcing facilities when compounding if there is a clinical need.
European Pharmaceutical Review explores some of the latest developments in outsourcing, including clinical development and production agreements; acquisitions and collaborations; and expansions.
Dr Saurabh Kumar Banerjee explains how Raman spectroscopy can be utilised to analyse medicine quality and detect counterfeit drugs over the course of the COVID-19 pandemic.
Pharmaceutical process development involves multi-disciplinary groups of chemists and analysts whose goal it is to create the API by the cheapest, most efficient route while ensuring product safety through effective impurity control measures.
Smita Deshmukh describes the current state of the global drug intermediates market, while suggesting how it will grow in the future.
Dr William Sanders discusses trends in the development and manufacture of highly potent active pharmaceutical ingredients (HPAPIs) and toxic payloads for antibody drug conjugates (ADCs).
Dr Abhishek Dadhich rounds up how the Indian pharmaceutical market has been impacted by the coronavirus pandemic and the steps the country’s government could take to overcome these setbacks.
The developers of the novel formulation, containing the cannabinoids CBDV and CBGA, now intend to test the clinical safety and efficacy of its anti-cancer activity.
With concerns rising about medicine availability during the global COVID-19 coronavirus pandemic, European Pharmaceutical Review explores how the pharmaceutical supply chain is faring.
A study comparing the V-Go device administering regular human insulin and rapid acting insulin analogues found they were equally effective and safe at controlling blood glucose.